BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21897065)

  • 1. [Development of novel agents for multiple myeloma; now and the future].
    Hata H
    Rinsho Ketsueki; 2011 Aug; 52(8):603-8. PubMed ID: 21897065
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current development of new drugs in malignant lymphoma].
    Ogura M
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():715-30. PubMed ID: 23134034
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current status of clinical trials of novel agents for multiple myeloma].
    Kuroda J
    Rinsho Ketsueki; 2014 Oct; 55(10):2005-15. PubMed ID: 25297766
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapy sequencing strategies in multiple myeloma: who, what and why?
    Costello C; Mikhael JR
    Future Oncol; 2018 Jan; 14(2):95-99. PubMed ID: 29219615
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiple myeloma, version 1.2013.
    Anderson KC; Alsina M; Bensinger W; Biermann JS; Cohen AD; Devine S; Djulbegovic B; Faber EA; Gasparetto C; Hernandez-Illizaliturri F; Huff CA; Kassim A; Krishnan AY; Liedtke M; Meredith R; Raje N; Schriber J; Singhal S; Somlo G; Stockerl-Goldstein K; Treon SP; Weber D; Yahalom J; Yunus F; Shead DA; Kumar R
    J Natl Compr Canc Netw; 2013 Jan; 11(1):11-7. PubMed ID: 23307977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma--translation of trial results into reality.
    Moreau P; Rajkumar SV
    Lancet; 2016 Jul; 388(10040):111-3. PubMed ID: 27411865
    [No Abstract]   [Full Text] [Related]  

  • 7. [New drugs in the treatment of multiple myeloma].
    Oriol A; Motlló C
    Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapeutics in multiple myeloma.
    Stewart AK
    Hematology; 2012 Apr; 17 Suppl 1(0 1):S105-8. PubMed ID: 22507794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma therapies.
    Strobeck M
    Nat Rev Drug Discov; 2007 Mar; 6(3):181-2. PubMed ID: 17396289
    [No Abstract]   [Full Text] [Related]  

  • 10. [Molecular targeting agents for multiple myeloma].
    Fujii S; Abe M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel therapies for relapsed myeloma.
    Stewart AK
    Hematology Am Soc Hematol Educ Program; 2009; ():578-86. PubMed ID: 20008242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
    Kawada H; Arima N
    Nihon Jinzo Gakkai Shi; 2012; 54(5):586-92. PubMed ID: 22991837
    [No Abstract]   [Full Text] [Related]  

  • 13. Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement.
    Nahi H; Svedmyr E; Lerner R
    Eur J Haematol; 2014; 92(5):454-5. PubMed ID: 24330308
    [No Abstract]   [Full Text] [Related]  

  • 14. [Present status and perspective of targeted therapy for B-cell lymphoma].
    Ohmachi K
    Rinsho Ketsueki; 2011 Aug; 52(8):609-17. PubMed ID: 21897066
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
    Mele G; Spina A; Guaragna G; Giannotta A; Melpignano A; Quarta G
    Leuk Lymphoma; 2014 May; 55(5):1191-3. PubMed ID: 23829305
    [No Abstract]   [Full Text] [Related]  

  • 16. [Current treatment strategies with novel agents for multiple myeloma].
    Tokuhira M
    Rinsho Ketsueki; 2011 Aug; 52(8):587-602. PubMed ID: 21897064
    [No Abstract]   [Full Text] [Related]  

  • 17. Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis.
    Palacios C; Martín-Pérez R; López-Pérez AI; Pandiella A; López-Rivas A
    Leuk Res; 2010 Nov; 34(11):1533-8. PubMed ID: 20667592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapies in monoclonal gammopathies.
    Niesvizky R
    Hematology; 2012 Apr; 17 Suppl 1():S121-4. PubMed ID: 22507798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.